Methicillin-Resistant Staphylococcus aureus (MRSA) Epidemiology Analysis and Forecast to 2033
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Methicillin-Resistant Staphylococcus aureus (MRSA) Report Overview
In the 7MM, there were 714,131 hospitalized incident cases of Methicillin-Resistant Staphylococcus aureus (MRSA) in 2023. The hospitalized incident cases of Methicillin-Resistant Staphylococcus aureus (MRSA) will register an AGR of more than 1% during 2023-2033. Methicillin-resistant Staphylococcus aureus (MRSA) is a virulent, antibiotic-resistant bacteria that is associated with considerable morbidity and mortality. MRSA can be categorized according to the setting in which the infection was acquired, as either healthcare-associated MRSA (HA-MRSA), which is acquired in hospitals or nursing homes, or community-associated MRSA.
Methicillin-Resistant Staphylococcus aureus (MRSA) Market Outlook, 2023-2033 (Hospitalized Incident Cases)
Buy the Full Report for More Insights into the Methicillin-Resistant Staphylococcus aureus Market Forecast
The Methicillin-Resistant Staphylococcus aureus (MRSA) market research report provides an overview of the risk factors, comorbidities, and the global and historical epidemiological trends for MRSA in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan). The report includes a 10-year epidemiology forecast for the hospitalized incident cases of MRSA, segmented by sex and age (0–17 years, 18–64 years, and ≥65 years).
Market Size (2022) | 714,131 Cases |
AGR (2023-2033) | >1% |
Forecast Period | 2023 – 2032 |
Key Countries | · The US
· France · Germany · Spain · Italy · The UK · Japan |
Key Sex Segments | · Men
· Women |
Enquire & Decide | Discover the perfect solution for your business needs. Enquire now and let us help you make an informed decision before making a purchase. |
Methicillin-Resistant Staphylococcus aureus (MRSA) Market Segmentation by Country
The key countries across the 8MM are the US, France, Germany, Spain, Italy, the UK, and Japan. In 2023, the US accounted for the highest percentage of hospitalized incident cases of MRSA in the 7MM. However, Spain is expected to have the highest AGR during the forecast period.
`Methicillin-Resistant Staphylococcus aureus (MRSA) Market Analysis by Country, 2023 (%)
Buy the Full Report for More Country Insights into the MRSA Market
Methicillin-Resistant Staphylococcus aureus (MRSA) Market Segmentation by Sex
Based on sex, the multiple myeloma vaccine market can be segmented into men and women. In 2023, the hospitalized incident cases of MRSA in the 7MM were higher in men than women. Among the 8MM, Spain had the largest difference in the hospitalized incident cases of MM between men and women. Among the 7MM, Japan had the largest difference in hospitalized incident cases of MRSA between men and women.
Methicillin-Resistant Staphylococcus aureus (MRSA) Market Analysis by Sex, 2023 (%)
Buy the Full Report for More Sex Insights into the MRSA Market
Segments Covered in the Report
Methicillin-Resistant Staphylococcus aureus (MRSA) Market Country Outlook (Hospitalized Incident Cases)
- The US
- France
- Germany
- Spain
- Italy
- The UK
- Japan
Methicillin-Resistant Staphylococcus aureus (MRSA) Market Sex Outlook (Hospitalized Incident Cases)
- Men
- Women
Scope
- The methicillin-resistant Staphylococcus aureus (MRSA): Epidemiology Report and Model provide an overview of the risk factors, comorbidities, and global trends of MRSA in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).
- The report includes a 10-year epidemiology forecast for the hospitalized incident cases of MRSA, segmented by sex and age (0–17 years, 18–64 years, and ≥65 years).
- The hospitalized incident cases are further segmented by infection site (site A infections, which consist of types of pneumonia, skin, and soft tissue infections [SSTIs], and bloodstream infections [BSIs], and other infection sites, as well as site B infections, which included endocarditis and osteomyelitis).
- Additionally, the hospitalized incident cases are segmented by case definition (HA-MRSA and CA-MRSA) in these markets. The forecast methodology was kept consistent across the 7MM to allow for a meaningful comparison of the forecast hospitalized incident cases of MRSA across these markets.
Reasons to Buy
The MRSA Epidemiology series will allow you to –
- Develop business strategies by understanding the trends shaping and driving the global MRSA markets.
- Quantify patient populations in the global MRSA markets to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for MRSA therapeutics in each of the markets covered.
- Understand the magnitude of the MRSA population by age, sex, type, and infection site.
Table of Contents
Table
Figures
Frequently asked questions
-
How many hospitalized incident cases of Methicillin-Resistant Staphylococcus aureus (MRSA) were seen in the 8MM in 2023?
In 2023, there were 714,131 hospitalized incident cases of Methicillin-Resistant Staphylococcus aureus (MRSA) in the 8MM.
-
What will be the growth rate of the Methicillin-Resistant Staphylococcus aureus (MRSA) market?
The hospitalized incident cases of Methicillin-Resistant Staphylococcus aureus (MRSA) will register an AGR of more than 1% during 2023-2033.
-
Which was the leading sex segment in the Methicillin-Resistant Staphylococcus aureus (MRSA) market in 2023?
In 2023, the number of diagnosed prevalent cases of Methicillin-Resistant Staphylococcus aureus (MRSA) was higher in men in the 8MM combined.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.